Skip to main content

Table 2 CBMNcyt assay results and the effect of gender on the MN and NPB yields

From: Prognostic value of the micronucleus assay for clinical endpoints in neoadjuvant radiochemotherapy for rectal cancer

  Women
  MN/BNL NPB/BNL
min max median min max median
Before RCT (0Gy) 0.005 0.057 0.018 0.000 0.018 0.002
3Gy in vitro 0.032 0.498 0.251 0.001 0.093 0.029
During RCT (21.6Gy) 0.035 0.295 0.140 0.002 0.064 0.018
End RCT (50.4Gy) 0.089 0.593 0.232 0.006 0.241 0.027
1 year after RCT 0.018 0.184 0.081 0.005 0.025 0.008
2 years after RCT 0.012 0.099 0.040 0.002 0.042 0.005
  Men
  MN/BNL NPB/BNL
min max median min max median
Before RCT (0Gy) 0 0.03 0.012 0 0.027 0.002
3Gy in vitro 0.069 0.899 0.236 0.008 0.211 0.027
During RCT (21.6Gy) 0.047 0.231 0.119 0.003 0.084 0.017
End RCT (50.4Gy) 0.079 0.541 0.219 0.004 0.079 0.022
1 year after RCT 0.018 0.203 0.060 0.003 0.016 0.006
2 years after RCT 0.014 0.067 0.029 0.001 0.021 0.007
  1. RCT radiochemotherapy, MN micronuclei, BNL binuclear lymphocytes, NPB nucleoplasmatic bridges